Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ADH1B | P00325 | 1/20 | 0.50 |
| ▸ | ADH1C | P00326 | 1/20 | 0.50 |
| ▸ | ADH1A | P07327 | 1/20 | 0.50 |
| ▸ | ADH4 | P08319 | 1/20 | 0.50 |
| ▸ | ADH7 | P40394 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.46 |
| ▸ | MLYCD | O95822 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28345296 | 1.00 | FAAH (0.50) | FAAHMEN1KMT2AADH1BADH1C | |
| SCHEMBL2182220 | 1.00 | FAAH (0.50) | FAAHMEN1KMT2AADH1BADH1C | |
| SCHEMBL15444589 | 0.98 | FAAH (0.47) | FAAHMEN1KMT2AADH1BADH1C | |
| SCHEMBL4501645 | 0.98 | FAAH (0.47) | FAAHMEN1KMT2AADH1BADH1C | |
| SCHEMBL15961732 | 0.92 | TAS1R3 (0.49) | FAAHMEN1KMT2AADH1BADH1C | |
| SCHEMBL14370371 | 0.88 | FAAH (0.48) | FAAHMEN1KMT2AADH1BADH1C | |
| SCHEMBL2482308 | 0.86 | FAAH (0.69) | FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL2586958 | 0.86 | FAAH (0.69) | FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL5682814 | 0.86 | FAAH (0.69) | FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL2481774 | 0.86 | FAAH (0.69) | FAAHMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118255685-A | Tricyclic compound, pharmaceutical composition and application thereof | 珂阑(上海)医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20100184649-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184649-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | FAAH 1153/4885MEN1 4491/4885KMT2A 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.